The Effect of Vitamin K Supplementation on Glucose Metabolism
NCT ID: NCT00960973
Last Updated: 2011-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
42 participants
INTERVENTIONAL
2009-09-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)
NCT02366481
The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients
NCT04285450
Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)
NCT02959762
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
NCT01972113
Relation Between Plasma Vitamin K2 and Glycemic Control and Metabolic Parameters in Type 2 Diabetic Patients.
NCT04387019
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin K
Vitamin K supplementation (menatetrenone 30 mg, 3 times a day for 4 weeks)
Menatetrenone
Menatetrenone 30 mg, 3 times a day for 4 weeks
Placebo control
Placebo control
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Menatetrenone
Menatetrenone 30 mg, 3 times a day for 4 weeks
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects receiving medication related to diabetes or obesity
* Subjects receiving warfarin
20 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seoul National University Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chan Soo Shin, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Medical School
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Vitamin K
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.